Description
Toremifene is a selective estrogen receptor modulator (SERM) that also moderates androgen receptor activity as well. Toremifene displays anticancer chemotherapeutic and anti-angiogenic activities. Clinically, this compound is used to treat breast cancer and prostate cancer. Toremifene decreases microvessel density and induces remission of benign fibrous lesions in clinical settings with subjects experiencing desmoid tumors. Additionally, toremifene increases latency to tumor formation, decreases tumor number, and increases survival in animal models of prostate cancer.
References
Chang BY, Kim SA, Malla B, et al. The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells. Toxicol Res. 2011 Jun;27(2):85-93. PMID: 24278556.
Kawashima H, Tanaka T, Cheng JS, et al. Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol Res. 2004 Dec;32(6):406-10. PMID: 15316697.
Heidemann J, Ogawa H, Otterson MF, et al. Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases. Dis Colon Rectum. 2004 Jan;47(1):118-22. PMID: 14719159.
Raghow S, Hooshdaran MZ, Katiyar S, et al. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 2002 Mar 1;62(5):1370-6. PMID: 11888907.
